{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:54:08Z","timestamp":1788648848877,"version":"build-2803163510"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.bone.2021.115901","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T22:09:09Z","timestamp":1614031749000},"page":"115901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Adverse events associated with bone-directed therapies in patients with cancer"],"prefix":"10.1016","volume":"158","author":[{"given":"Mark A.","family":"Jara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeena","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi I.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bone.2021.115901_bb0005","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2000.18.7.1570","article-title":"Osteoporosis due to cancer treatment: pathogenesis and management","volume":"18","author":"Pfeilschifter","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bone.2021.115901_bb0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/era.11.204","article-title":"Denosumab for the management of bone disease in patients with solid tumors","volume":"12","author":"Body","year":"2012","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.bone.2021.115901_bb0015","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/bonekey.2015.122","article-title":"Mechanisms of osteolytic and osteoblastic skeletal lesions","volume":"4","author":"David Roodman","year":"2015","journal-title":"Bonekey Rep"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2021.115901_bb0020","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1053\/j.seminoncol.2010.06.006","article-title":"Safety considerations for use of bone-targeted agents in patients with cancer","volume":"37","author":"Mortimer","year":"2010","journal-title":"Semin. Oncol."},{"issue":"9","key":"10.1016\/j.bone.2021.115901_bb0025","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"issue":"12 Suppl","key":"10.1016\/j.bone.2021.115901_bb0030","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.bone.2021.115901_bb0035","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int. J. Clin. Pract."},{"issue":"4","key":"10.1016\/j.bone.2021.115901_bb0040","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.bone.2021.115901_bb0045","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy","volume":"99","author":"Hu","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.bone.2021.115901_bb0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/1078155207080806","article-title":"Significance and impact of bisphosphonate-induced acute phase responses","volume":"13","author":"Olson","year":"2007","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"6","key":"10.1016\/j.bone.2021.115901_bb0055","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jbmr.5650100617","article-title":"Interleukin-6 and the acute phase response during treatment of patients with Paget\u2019s disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate","volume":"10","author":"Schweitzer","year":"1995","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2021.115901_bb0060","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s002239900353","article-title":"An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates","volume":"61","author":"Thiebaud","year":"1997","journal-title":"Calcif. Tissue Int."},{"issue":"9","key":"10.1016\/j.bone.2021.115901_bb0065","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","article-title":"Characterization of and risk factors for the acute-phase response after zoledronic acid","volume":"95","author":"Reid","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2021.115901_bb0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2008.07435.x","article-title":"Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP\/DMAPP","volume":"144","author":"Roelofs","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.bone.2021.115901_bb0075","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2147\/CIA.S2046","article-title":"Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women","volume":"3","author":"Lambrinoudaki","year":"2008","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.bone.2021.115901_bb0080","doi-asserted-by":"crossref","unstructured":"F. Saad, D.M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, J.L. Chin, J.J. Vinholes, J.A. Goas, B. Chen, G. Zoledronic Acid Prostate Cancer Study, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J Natl Cancer Inst 94(19) (2002) 1458\u201368.","DOI":"10.1093\/jnci\/94.19.1458"},{"issue":"15","key":"10.1016\/j.bone.2021.115901_bb0085","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"35","key":"10.1016\/j.bone.2021.115901_bb0090","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bone.2021.115901_bb0095","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.bone.2021.115901_bb0100","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2021.115901_bb0105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/1752-1947-5-367","article-title":"Life-threatening hyperkalemia following zoledronic acid infusion for Paget\u2019s disease: a case report","volume":"5","author":"Panteliou","year":"2011","journal-title":"J. Med. Case Rep."},{"issue":"3","key":"10.1016\/j.bone.2021.115901_bb0110","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1574886311666160426141647","article-title":"Zoledronate induced Hypocalcemia and hypophosphatemia in osteoporosis: a cause of concern","volume":"11","author":"Kaur","year":"2016","journal-title":"Curr. Drug Saf."},{"issue":"2","key":"10.1016\/j.bone.2021.115901_bb0115","doi-asserted-by":"crossref","first-page":"96","DOI":"10.14310\/horm.2002.1226","article-title":"Bisphosphonate-associated adverse events","volume":"8","author":"Papapetrou","year":"2009","journal-title":"Hormones (Athens)"},{"issue":"9","key":"10.1016\/j.bone.2021.115901_bb0120","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1185\/03007995.2013.813840","article-title":"Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies","volume":"29","author":"Qi","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"10.1016\/j.bone.2021.115901_bb0125","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s13181-016-0543-y","article-title":"A RANKL wrinkle: Denosumab-induced Hypocalcemia","volume":"12","author":"Laskowski","year":"2016","journal-title":"J Med Toxicol"},{"issue":"13","key":"10.1016\/j.bone.2021.115901_bb0130","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","volume":"51","author":"Body","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"16","key":"10.1016\/j.bone.2021.115901_bb0135","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.bone.2021.115901_bb0140","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/02841860701233435","article-title":"The use of bisphosphonates in cancer patients","volume":"46","author":"Wu","year":"2007","journal-title":"Acta Oncol."},{"issue":"2","key":"10.1016\/j.bone.2021.115901_bb0145","first-page":"172","article-title":"A case of severe","volume":"29","author":"Clark","year":"2016","journal-title":"Prolonged, Refractory Hypophosphatemia After Zoledronic Acid Administration, J Pharm Pract"},{"issue":"3","key":"10.1016\/j.bone.2021.115901_bb0150","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11739-019-02048-w","article-title":"Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis","volume":"14","author":"Tufano","year":"2019","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.bone.2021.115901_bb0155","doi-asserted-by":"crossref","unstructured":"S.L. Ruggiero, T.B. Dodson, J. Fantasia, R. Goodday, T. Aghaloo, B. Mehrotra, F. O'Ryan, O. American Association of, S. Maxillofacial, American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update, J Oral Maxillofac Surg 72(10) (2014) 1938\u201356.","DOI":"10.1016\/j.joms.2014.04.031"},{"issue":"9","key":"10.1016\/j.bone.2021.115901_bb0160","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2021.115901_bb0165","doi-asserted-by":"crossref","unstructured":"S.L. Ruggiero, T.B. Dodson, L.A. Assael, R. Landesberg, R.E. Marx, B. Mehrotra, O. American Association of, S. Maxillofacial, American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update, J Oral Maxillofac Surg 67(5 Suppl) (2009) 2\u201312.","DOI":"10.1016\/j.joms.2009.01.009"},{"key":"10.1016\/j.bone.2021.115901_bb0170","doi-asserted-by":"crossref","unstructured":"A.A. Khan, A. Morrison, D.A. Hanley, D. Felsenberg, L.K. McCauley, F. O'Ryan, I.R. Reid, S.L. Ruggiero, A. Taguchi, S. Tetradis, N.B. Watts, M.L. Brandi, E. Peters, T. Guise, R. Eastell, A.M. Cheung, S.N. Morin, B. Masri, C. Cooper, S.L. Morgan, B. Obermayer-Pietsch, B.L. Langdahl, R. Al Dabagh, K.S. Davison, D.L. Kendler, G.K. Sandor, R.G. Josse, M. Bhandari, M. El Rabbany, D.D. Pierroz, R. Sulimani, D.P. Saunders, J.P. Brown, J. Compston, J. International Task Force on Osteonecrosis of the, Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus, J Bone Miner Res 30(1) (2015) 3\u201323.","DOI":"10.1002\/jbmr.2405"},{"issue":"1","key":"10.1016\/j.bone.2021.115901_bb0175","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jdsr.2018.11.002","article-title":"Symposium: imaging modalities for drug-related osteonecrosis of the jaw (6), assessment of mandibular metabolism due to long-term administration of an anti-resorptive agent by bone scintigraphy (secondary publication)","volume":"55","author":"Ohbayashi","year":"2019","journal-title":"Jpn Dent Sci Rev"},{"issue":"5 Suppl","key":"10.1016\/j.bone.2021.115901_bb0180","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"3 Suppl","key":"10.1016\/j.bone.2021.115901_bb0185","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1532-3382(12)70046-5","article-title":"Antiresorptives and osteonecrosis of the jaw","volume":"12","author":"Yamashita","year":"2012","journal-title":"J Evid Based Dent Pract"},{"issue":"6","key":"10.1016\/j.bone.2021.115901_bb0190","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115901_bb0195","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41413-020-0088-1","article-title":"Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors","volume":"8","author":"Wan","year":"2020","journal-title":"Bone Res"},{"issue":"7","key":"10.1016\/j.bone.2021.115901_bb0200","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.oraloncology.2009.01.002","article-title":"Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): a concise update","volume":"45","author":"Bagan","year":"2009","journal-title":"Oral Oncol."},{"issue":"4","key":"10.1016\/j.bone.2021.115901_bb0205","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clgc.2014.12.002","article-title":"Osteonecrosis of the jaw in patients with metastatic renal cell Cancer treated with bisphosphonates and targeted agents: results of an Italian multicenter study and review of the literature","volume":"13","author":"Fusco","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.bone.2021.115901_bb0210","doi-asserted-by":"crossref","first-page":"8071579","DOI":"10.1155\/2018\/8071579","article-title":"Osteonecrosis of the jaw associated with Antiangiogenics in Antiresorptive-naive patient: a comprehensive review of the literature","volume":"2018","author":"Pimolbutr","year":"2018","journal-title":"Biomed. Res. Int."},{"issue":"24","key":"10.1016\/j.bone.2021.115901_bb0215","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bone.2021.115901_bb0220","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000313680","article-title":"Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib","volume":"33","author":"Bozas","year":"2010","journal-title":"Onkologie"},{"issue":"4","key":"10.1016\/j.bone.2021.115901_bb0225","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tripleo.2010.04.049","article-title":"Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases","volume":"110","author":"Hoefert","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"Suppl. 2","key":"10.1016\/j.bone.2021.115901_bb0230","article-title":"Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma","volume":"102","author":"Garuti","year":"2016","journal-title":"Tumori"},{"issue":"5","key":"10.1016\/j.bone.2021.115901_bb0235","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.joms.2009.10.010","article-title":"Osteonecrosis of the jaw in a patient on Denosumab","volume":"68","author":"Aghaloo","year":"2010","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2021.115901_bb0240","doi-asserted-by":"crossref","first-page":"1801676","DOI":"10.1155\/2016\/1801676","article-title":"Medication-related osteonecrosis of the jaws: considerations on a new Antiresorptive therapy (Denosumab) and treatment outcome after a 13-year experience","volume":"2016","author":"Favia","year":"2016","journal-title":"Int J Dent"},{"issue":"7","key":"10.1016\/j.bone.2021.115901_bb0245","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.bone.2021.115901_bb0250","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bone.2021.115901_bb0255","doi-asserted-by":"crossref","unstructured":"D.A. Tyndall, J.B. Price, S. Tetradis, S.D. Ganz, C. Hildebolt, W.C. Scarfe, O. American Academy of, R. Maxillofacial, Position statement of the American Academy of Oral and Maxillofacial Radiology on selection criteria for the use of radiology in dental implantology with emphasis on cone beam computed tomography, Oral Surg Oral Med Oral Pathol Oral Radiol 113(6) (2012) 817\u201326.","DOI":"10.1016\/j.oooo.2012.03.005"},{"issue":"3","key":"10.1016\/j.bone.2021.115901_bb0260","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"issue":"25","key":"10.1016\/j.bone.2021.115901_bb0265","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2021.115901_bb0270","doi-asserted-by":"crossref","first-page":"2684924","DOI":"10.1155\/2018\/2684924","article-title":"The dental Management of Patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention","volume":"2018","author":"Di Fede","year":"2018","journal-title":"Biomed. Res. Int."},{"issue":"32","key":"10.1016\/j.bone.2021.115901_bb0275","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bone.2021.115901_bb0280","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijom.2012.06.020","article-title":"Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study","volume":"41","author":"Yamazaki","year":"2012","journal-title":"Int. J. Oral Maxillofac. Surg."},{"issue":"9","key":"10.1016\/j.bone.2021.115901_bb0285","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.oraloncology.2012.03.009","article-title":"Tooth extraction in patients on zoledronic acid therapy","volume":"48","author":"Mozzati","year":"2012","journal-title":"Oral Oncol."},{"issue":"7","key":"10.1016\/j.bone.2021.115901_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201343","article-title":"Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: is tooth extraction a risk factor?","volume":"13","author":"Soutome","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bone.2021.115901_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e03795","article-title":"Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): a systematic review","volume":"6","author":"Ottesen","year":"2020","journal-title":"Heliyon"},{"issue":"11","key":"10.1016\/j.bone.2021.115901_bb0300","doi-asserted-by":"crossref","first-page":"6439","DOI":"10.21873\/anticanres.13005","article-title":"Atypical femoral fractures (AFF) from Bone remodeling agents in patients with Cancer","volume":"38","author":"Kordoni","year":"2018","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.bone.2021.115901_bb0305","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1186\/s12885-019-6236-6","article-title":"Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review","volume":"19","author":"Takahashi","year":"2019","journal-title":"BMC Cancer"},{"issue":"14","key":"10.1016\/j.bone.2021.115901_bb0310","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.160450","article-title":"Atypical femoral fracture","volume":"189","author":"Khan","year":"2017","journal-title":"CMAJ"},{"issue":"4","key":"10.1016\/j.bone.2021.115901_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8040","article-title":"A systematic review of the role of bisphosphonates in metastatic disease","volume":"8","author":"Ross","year":"2004","journal-title":"Health Technol. Assess."},{"issue":"2","key":"10.1016\/j.bone.2021.115901_bb0320","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1677\/erc.0.0110207","article-title":"The role of bisphosphonates in breast and prostate cancers","volume":"11","author":"Brown","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bone.2021.115901_bb0325","doi-asserted-by":"crossref","unstructured":"N. Pavlakis, R. Schmidt, M. Stockler, Bisphosphonates for breast cancer, Cochrane Database Syst Rev (3) (2005) CD003474.","DOI":"10.1002\/14651858.CD003474.pub2"},{"issue":"6","key":"10.1016\/j.bone.2021.115901_bb0330","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00264-013-2259-9","article-title":"Atypical femoral fractures after anti-osteoporotic medication: a Korean multicenter study","volume":"38","author":"Kang","year":"2014","journal-title":"Int. Orthop."},{"key":"10.1016\/j.bone.2021.115901_bb0335","doi-asserted-by":"crossref","unstructured":"E. Shane, D. Burr, B. Abrahamsen, R.A. Adler, T.D. Brown, A.M. Cheung, F. Cosman, J.R. Curtis, R. Dell, D.W. Dempster, P.R. Ebeling, T.A. Einhorn, H.K. Genant, P. Geusens, K. Klaushofer, J.M. Lane, F. McKiernan, R. McKinney, A. Ng, J. Nieves, R. O'Keefe, S. Papapoulos, T.S. Howe, M.C. van der Meulen, R.S. Weinstein, M.P. Whyte, Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research, J Bone Miner Res 29(1) (2014) 1\u201323.","DOI":"10.1002\/jbmr.1998"},{"issue":"33","key":"10.1016\/j.bone.2021.115901_bb0340","doi-asserted-by":"crossref","first-page":"8722","DOI":"10.1073\/pnas.1704460114","article-title":"Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance","volume":"114","author":"Lloyd","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.bone.2021.115901_bb0345","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11914-014-0200-9","article-title":"Atypical femoral fractures, bisphosphonates, and mechanical stress","volume":"12","author":"Aspenberg","year":"2014","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.bone.2021.115901_bb0350","doi-asserted-by":"crossref","unstructured":"A. Unnanuntana, A. Saleh, K.A. Mensah, J.P. Kleimeyer, J.M. Lane, Atypical femoral fractures: what do we know about them?: AAOS Exhibit Selection, J Bone Joint Surg Am 95(2) (2013) e8 1\u201313.","DOI":"10.2106\/JBJS.L.00568"},{"issue":"12","key":"10.1016\/j.bone.2021.115901_bb0355","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2021.115901_bb0360","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/annonc\/mdv014","article-title":"Atypical femur fractures associated with use of bisphosphonates and denosumab","volume":"26","author":"Farooki","year":"2015","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.bone.2021.115901_bb0365","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/jbmr.2818","article-title":"Incidence of atypical femur fractures in Cancer patients: the MD Anderson Cancer Center experience","volume":"31","author":"Edwards","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115901_bb0370","unstructured":"F.D.S. Communication, Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures, 2010. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-safety-update-osteoporosis-drugs-bisphosphonates-and-atypical. (Accessed 11\/29 2020)."},{"key":"10.1016\/j.bone.2021.115901_bb0375","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12891-016-1086-8","article-title":"Management of atypical femoral fracture: a scoping review and comprehensive algorithm","volume":"17","author":"Toro","year":"2016","journal-title":"BMC Musculoskelet. Disord."},{"issue":"6","key":"10.1016\/j.bone.2021.115901_bb0380","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/BOT.0b013e31827240ae","article-title":"Surgical treatment improves clinical and functional outcomes for patients who sustain incomplete bisphosphonate-related femur fractures","volume":"27","author":"Egol","year":"2013","journal-title":"J. Orthop. Trauma"},{"issue":"17","key":"10.1016\/j.bone.2021.115901_bb0385","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bone.2021.115901_bb0390","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0773.1997.tb01964.x","article-title":"Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models","volume":"80","author":"Green","year":"1997","journal-title":"Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/j.bone.2021.115901_bb0395","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"Markowitz","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.bone.2021.115901_bb0400","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000366450","article-title":"Collapsing focal segmental glomerulosclerosis resulting from a single dose of zoledronate","volume":"4","author":"Neyra","year":"2014","journal-title":"Nephron Extra"},{"issue":"11","key":"10.1016\/j.bone.2021.115901_bb0405","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int."},{"issue":"1\u20132","key":"10.1016\/j.bone.2021.115901_bb0410","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0300-483X(90)90088-X","article-title":"Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD), in rats and mice","volume":"65","author":"Cal","year":"1990","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.bone.2021.115901_bb0415","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/JOP.2011.000486","article-title":"Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project","volume":"9","author":"Edwards","year":"2013","journal-title":"J Oncol Pract"},{"issue":"4","key":"10.1016\/j.bone.2021.115901_bb0420","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1200\/JOP.0748502","article-title":"2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma: guideline summary","volume":"3","author":"ASCO","year":"2007","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.bone.2021.115901_bb0425","unstructured":"FDA, HIGHLIGHTS OF PRESCRIBING INFORMATION. Zolendronic acid, 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/203231s011lbl.pdf. (Accessed 11\/29 2020)."},{"issue":"2","key":"10.1016\/j.bone.2021.115901_bb0430","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3899\/jrheum.161270","article-title":"Occurrence of serious infection in patients with rheumatoid arthritis treated with biologics and Denosumab observed in a clinical setting","volume":"45","author":"Lau","year":"2018","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2021.115901_bb0435","doi-asserted-by":"crossref","unstructured":"R.K. Dore, The RANKL pathway and denosumab, Rheum Dis Clin North Am 37(3) (2011) 433\u201352, vi-vii.","DOI":"10.1016\/j.rdc.2011.07.004"},{"issue":"2","key":"10.1016\/j.bone.2021.115901_bb0440","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00198-010-1326-y","article-title":"Do RANKL inhibitors (denosumab) affect inflammation and immunity?","volume":"22","author":"Ferrari-Lacraz","year":"2011","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2021.115901_bb0445","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","article-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","volume":"23","author":"Watts","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"5","key":"10.1016\/j.bone.2021.115901_bb0450","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz322","article-title":"Risk for infections during treatment with Denosumab for osteoporosis: a systematic review and meta-analysis","volume":"105","author":"Diker-Cohen","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.bone.2021.115901_bb0455","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bone.2021.115901_bb0460","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9768","key":"10.1016\/j.bone.2021.115901_bb0465","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2021.115901_bb0470","unstructured":"AMGEN, Xgeva\u25bc (denosumab): risk of new primary malignancy, 2018. https:\/\/assets.publishing.service.gov.uk\/media\/5b2ccd01ed915d587f69eec5\/Xgeva-DHPC-1605_signed.pdf. (Accessed 11\/29 2020)."},{"key":"10.1016\/j.bone.2021.115901_bb0475","doi-asserted-by":"crossref","unstructured":"P.D. Miller, M.A. Bolognese, E.M. Lewiecki, M.R. McClung, B. Ding, M. Austin, Y. Liu, J. San Martin, G. Amg Bone Loss Study, Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial, Bone 43(2) (2008) 222\u20139.","DOI":"10.1016\/j.bone.2008.04.007"},{"issue":"1","key":"10.1016\/j.bone.2021.115901_bb0480","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","article-title":"Bone mineral density changes after 1 year of Denosumab discontinuation in postmenopausal women with long-term Denosumab treatment for osteoporosis","volume":"103","author":"Popp","year":"2018","journal-title":"Calcif. Tissue Int."},{"issue":"5","key":"10.1016\/j.bone.2021.115901_bb0485","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos. Int."},{"issue":"5","key":"10.1016\/j.bone.2021.115901_bb0490","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00198-016-3553-3","article-title":"Cancel the denosumab holiday","volume":"27","author":"McClung","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.bone.2021.115901_bb0495","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of Denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2021.115901_bb0500","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-019-05458-8","article-title":"Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors","volume":"179","author":"Gonzalez-Rodriguez","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.bone.2021.115901_bb0505","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","volume":"17","author":"Lamy","year":"2019","journal-title":"Curr Osteoporos Rep."},{"issue":"33","key":"10.1016\/j.bone.2021.115901_bb0510","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1200\/JCO.2010.28.7524","article-title":"Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer","volume":"28","author":"Wilkinson","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bone.2021.115901_bb0515","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/bjc.2011.338","article-title":"Intravenous bisphosphonate therapy and atrial fibrillation\/flutter risk in cancer patients: a nationwide cohort study","volume":"105","author":"Erichsen","year":"2011","journal-title":"Br. J. Cancer"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221000636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221000636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:00:12Z","timestamp":1757613612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328221000636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":103,"alternative-id":["S8756328221000636"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.115901","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events associated with bone-directed therapies in patients with cancer","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.115901","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115901"}}